Fulvestrant vs Tamoxifen (Soltamox)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Fulvestrant · Faslodex

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT00635713 · Phase 3 · completed

The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)

Result source: NCT01602380

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFulvestrantTamoxifen (Soltamox)
PFS, median4.7 vs 3.8+0.9 vs placebon 146NCT00390455
17 other results
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results
OS, median29.9 vs 26.4+3.5 vs placebon 146NCT00390455
10 other results
47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result
ORR20% vs 9%+11 vs placebon 101NCT00390455
9 other results
  • 13% vs 23% n 32 · Phase 3 · secondary NCT00390455
  • 38% vs 17% n 8 · Phase 3 · secondary NCT00390455
  • 46.1% vs 44.9% 500 mg · n 193 · Phase 3 · secondary NCT01602380
  • 29.9% n 45 · Phase 2 · primary NCT02860000
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 19.3% n 119 · Phase 2 · secondary NCT03056755
  • 17.5% n 114 · Phase 2 · secondary NCT03056755
  • 25.2% n 115 · Phase 2 · secondary NCT03056755
30%bn 47NCT02668666
Clinical benefit rate78.3% vs 74.1%vs Anastrozole500 mg · n 230NCT01602380
9 other results
  • 55% vs 55.1% n 258 · Phase 3 · secondary NCT00256698
  • 70% n 345 · Phase 3 · secondary NCT00075764
  • 73% n 349 · Phase 3 · secondary NCT00075764
  • 58.2% vs 38% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 45.6% vs 38% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 28.9% wk 24 · n 45 · Phase 2 · secondary NCT02860000
  • 46.2% n 119 · Phase 2 · secondary NCT03056755
  • 35.1% n 114 · Phase 2 · secondary NCT03056755
  • 38.3% n 115 · Phase 2 · secondary NCT03056755
64%bn 47NCT02668666

PFS, median

Fulvestrant
4.7 vs 3.8+0.9 vs placebon 146NCT00390455
17 other results
Tamoxifen (Soltamox)
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results

OS, median

Fulvestrant
29.9 vs 26.4+3.5 vs placebon 146NCT00390455
10 other results
Tamoxifen (Soltamox)
47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result

ORR

Fulvestrant
20% vs 9%+11 vs placebon 101NCT00390455
9 other results
  • 13% vs 23% n 32 · Phase 3 · secondary NCT00390455
  • 38% vs 17% n 8 · Phase 3 · secondary NCT00390455
  • 46.1% vs 44.9% 500 mg · n 193 · Phase 3 · secondary NCT01602380
  • 29.9% n 45 · Phase 2 · primary NCT02860000
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 19.3% n 119 · Phase 2 · secondary NCT03056755
  • 17.5% n 114 · Phase 2 · secondary NCT03056755
  • 25.2% n 115 · Phase 2 · secondary NCT03056755
Tamoxifen (Soltamox)
30%bn 47NCT02668666

Clinical benefit rate

Fulvestrant
78.3% vs 74.1%vs Anastrozole500 mg · n 230NCT01602380
9 other results
  • 55% vs 55.1% n 258 · Phase 3 · secondary NCT00256698
  • 70% n 345 · Phase 3 · secondary NCT00075764
  • 73% n 349 · Phase 3 · secondary NCT00075764
  • 58.2% vs 38% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 45.6% vs 38% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 28.9% wk 24 · n 45 · Phase 2 · secondary NCT02860000
  • 46.2% n 119 · Phase 2 · secondary NCT03056755
  • 35.1% n 114 · Phase 2 · secondary NCT03056755
  • 38.3% n 115 · Phase 2 · secondary NCT03056755
Tamoxifen (Soltamox)
64%bn 47NCT02668666
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. Fulvestrant: 11 of 11 rows · Tamoxifen (Soltamox): 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFulvestrant
Rows use multiple source trials
Tamoxifen (Soltamox)
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
70% (n=345)a,b,c,d
NCT00075764 · Phase 3 · registry result, not featured evidence
show 1 more dose
73% (n=349)
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
64% (n=47)b,c,d
NCT02668666 · Phase 2 · registry result, not featured evidence
Clinical Benefit
event count · % of participants
No placebo or comparator arm
47.7% (n=111)*500 mge,c,f
NCT01300351 · Phase 3 · registry result, not featured evidence · converted to % from 53 patients as posted
5 other source trials
83.3% (n=54)*
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
30% (n=10)*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
38.1% (n=21)*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted
18.5% (n=27) @ 24wk*
NCT01142401 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
21.9% (n=32) @ 24wk*
NCT02953860 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
50% (n=2) @ 26wk*a,e,c,f
NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
show 1 more dose
100% (n=2)*
NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
ORR
event count · % of participants
No placebo or comparator arm
28.1% (n=57)*500 mgb,c,f,d
NCT01300351 · Phase 3 · registry result, not featured evidence · converted to % from 16 patients as posted
3 other source trials
33.3% (n=54)*
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted
30% (n=10)*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
23.8% (n=21)*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
18.6% (n=43) @ 24wk*b,c,f,d
NCT00365599 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
29.9% (n=45)c,f,d
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
3 other source trials
19.3% (n=119)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
17.5% (n=114)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
25.2% (n=115)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30% (n=47)c,f,d
NCT02668666 · Phase 2 · registry result, not featured evidence
Overall Survival
time to event · months
No placebo or comparator arm
41.3 monthsa,e,c,d
NCT00075764 · Phase 3 · registry result, not featured evidence
show 1 more dose
47.7 months
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
18.7541 monthse,c,d
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
8 months500 mgb,c,f,d
NCT01300351 · Phase 3 · registry result, not featured evidence
7 other source trials
29.4 months*
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted
5.4 months
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
8 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
5.6 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
5.6 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
4.62 months*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to months from 20 weeks as posted
5.54 months*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to months from 24 weeks as posted
9.13 monthsb,c,f,d
NCT02668666 · Phase 2 · registry result, not featured evidence
2 other source trials
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
Time to Progression
time to event · months
No placebo or comparator arm
13.5 monthsa,b,c,d
NCT00075764 · Phase 3 · registry result, not featured evidence
show 1 more dose
15 months
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
10.3 monthsb,c,d
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
89.1%500 mgg
NCT01602380 · Phase 3 · combination
show 40 more results
47.5%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.2%
NCT02447328 · Phase 4 · registry result, not featured evidence
0%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
0%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
n/a: no completion milestoneArm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
21.6%
NCT00390455 · Phase 3 · registry result, not featured evidence
32.4%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
64.7%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
8.2%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
99.2%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
100%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
92.1%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
9.1%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
12.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
3.4%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
69.6%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
76.6%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
66.7%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
0%g
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
0.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT01027416 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—500 mgg
NCT01602380 · Phase 3 · combination
show 40 more results
10%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—
NCT02447328 · Phase 4 · registry result, not featured evidence
—Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
—Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
2%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
1.4%Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
3.4%Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
11.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
0%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
5%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
15.7%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
11.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.3%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
—
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
0%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
2.1%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
3.9%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
—g
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
—
NCT00036270 · Phase 3 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—
NCT01027416 · Phase na · registry result, not featured evidence
Serious AEs
17.1%500 mgg
NCT01602380 · Phase 3 · combination
show 40 more results
25%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
16.9%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
13.8%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
14.1%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
6.2%Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
13.8%Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
—Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
8.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
3.7%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
15.6%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
25%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30.2%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
0%Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
18.2%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
37.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
10.5%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
18.5%Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
6.3%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
8.7%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
8.5%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
18%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
28.7%g
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
17.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01027416 · Phase na · registry result, not featured evidence
Most frequent reported AEs
500 mgg
arthralgia 18.4%
fatigue 12.7%
hot flush 11.4%
NCT01602380 · Phase 3 · combination
show 33 more results
hyperglycaemia 90%
stomatitis 37.5%
diarrhoea 35%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
myalgia 12.3%
nausea 12.3%
back pain 11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
lethargy 64.5%
arthralgia 42%
hot flush 37.2%
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
lethargy 64.4%
vomiting 44.9%
arthralgia 43.6%
NCT00253422 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
fatigue (asthenia, lethargy, malaise) 60.2%
hot flashes/flushes 45.7%
pain - joint 45.1%
NCT00075764 · Phase 3 · registry result, not featured evidence
fatigue (asthenia, lethargy, malaise) 63.2%
hot flashes/flushes 54.3%
pain - joint 44%
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
diarrhea 62.4% (placebo 21.9%)
fatigue 55.3% (placebo 53.3%)
rash acneiform 41.1% (placebo 4.4%)
NCT00390455 · Phase 3 · registry result, not featured evidence
500 mg
injection site reaction 11%
pyrexia 10.1%
fatigue 8.3%
NCT01300351 · Phase 3 · registry result, not featured evidence
arthralgia 11.7%
fatigue 10.5%
nausea 9%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
fatigue 83.3%
anemia 62.5%
neutrophil count decreased 60.4%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 64.6%
hyperglycaemia 59.8%
nausea 46.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
asthenia 100%
blood creatinine increased 100%
diarrhoea 100%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 68.3%
hyperglycaemia 64.3%
nausea 54%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 67.5%
diarrhoea 54%
nausea 40.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70%
hyperglycaemia 60%
fatigue 50%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
vomiting 60%
anorexia 40%
constipation 40%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 81.8%
anorexia 63.6%
aspartate aminotransferase increased 45.5%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 91.7%
fatigue 50%
nausea 50%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 61.4%
thrombocytopenia 61.4%
nausea 59.6%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 55.6%
thrombocytopenia 55.6%
diarrhea 51.9%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
fatigue 53.1%
nausea 50%
achiness 43.8%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
fatigue 76.9%
anorexia 61.5%
pain 53.8%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
500 mg
back pain 15.2%
fatigue 15.2%
nausea 15.2%
NCT00313170 · Phase 2 · registry result, not featured evidence
250 mg
nausea 25.5%
hot flush 19.1%
cough 12.8%
NCT00313170 · Phase 2 · registry result, not featured evidence
250 mg + loading dose
fatigue 22%
nausea 18%
back pain 16%
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
g
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 11 more results
hot flush 31.3%
arthralgia 23.8%
fatigue 16.4%
NCT00036270 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
arthralgia 33.3%
back pain 33.3%
headache 33.3%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
blood and lymphatic system disorders - other 50%
hypertension 50%
neutrophil count decreased 50%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
headache 32.1% (placebo 0%)
night sweats 32.1% (placebo 0%)
irritability 28.6% (placebo 0%)
NCT01027416 · Phase na · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dThe assessment timepoint is not available for both results.
  5. eTrial phases differ: Phase 1 versus Phase 3.
  6. fTreatment context has not been resolved for both arms.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fulvestrant

All-cause Mortality 68.3% (n=230) vs 67.7% (n=232) Anastrozole500 mg
absolute value · percentage points
NCT01602380 · Phase 3 · combination
ORR 46.1% (n=193) vs 44.9% (n=196) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 5 more results
32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
20% (n=101) vs 9% (n=103) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
13% (n=32) vs 23% (n=32) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
38% (n=8) vs 17% (n=13) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
Duration of Response 20 vs 13.2 Anastrozole months500 mg
time to event · months
NCT01602380 · Phase 3 · combination
show 6 more results
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
10.2 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
8.7 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
22.3 vs 18.2 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Clinical Benefit 78.3% (n=230) vs 74.1% (n=232) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 3 more results
58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
55% (n=258) vs 55.1% (n=256) Anastrozole
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
ORR 7.1% (n=226) vs 4.2% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 16 Participants as posted
show 2 more results
7.3% (n=233) vs 4.2% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
22.8% (n=206) vs 29.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
Clinical Benefit 24.3% (n=226) vs 23.8% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
show 2 more results
28.3% (n=233) vs 23.8% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 Participants as posted
76.2% (n=206) vs 82.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
Duration of Clinical Benefit 11.2 vs 12.2 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
11.5 vs 12.2 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
18.5 vs 18.1 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Time to Treatment Failure 3.8 vs 3.4 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
3.9 vs 3.4 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
12.4 vs 11.4 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -1.09 vs -4.97 Capecitabine score
absolute change · score
Role functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 6.78 vs 8.67 Capecitabine score
absolute change · score
Emotional functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 60 further endpoints in the CSV export.

Tamoxifen (Soltamox)

PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Disease Free Survival 352 vs 388 Tamoxifen Followed by Exemestane count @ 143wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
show 1 more result
712 vs 714 Tamoxifen Followed by Exemestane count @ 260wk
NCT00036270 · Phase 3 · registry result, not featured evidence
Overall Survival 485 vs 476 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
Relapse Free Survival 499 vs 521 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
OS Rate at 12 75.63% (n=49) @ 104wk
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Pathologic Complete 0% (n=23) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT02988986 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
7.7% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted
Overall 100% (n=13)
responder rate · % of participants
No placebo or comparator arm
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 13 participants as posted
Breast Conserving Surgery 0% (n=15)
event count · % of participants
No placebo or comparator arm
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 0 participants as posted
Ki67 -3.4% (n=9) vs -5.1% (n=9) Tamoxifen Citrate
absolute change · percentage points
NCT00952731 · Phase 2 · registry result, not featured evidence · combination

Breast Cancer

Shared mechanism: Estrogen receptor · full Breast Cancer pipeline

Fulvestrant · Faslodex

Marketed by AstraZeneca

Approved in Breast Cancersmall molecule
Partial signal

NCT00635713 · Phase 3 · completed

The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)

Result source: NCT01602380

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

Reported efficacy

Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) (mixed)

Result source: NCT00066690

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Fulvestrant: 11 of 11 rows · Tamoxifen (Soltamox): 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFulvestrant
Rows use multiple source trials
Tamoxifen (Soltamox)
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
70% (n=345)a,b,c,d
NCT00075764 · Phase 3 · registry result, not featured evidence
show 1 more dose
73% (n=349)
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
64% (n=47)b,c,d
NCT02668666 · Phase 2 · registry result, not featured evidence
ORR
event count · % of participants
No placebo or comparator arm
28.1% (n=57)*500 mgb,c,e,d
NCT01300351 · Phase 3 · registry result, not featured evidence · converted to % from 16 patients as posted
5 other source trials
0% (n=3)*
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
3.7% (n=27)*
NCT03620643 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
33.3% (n=54)*
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted
30% (n=10)*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
23.8% (n=21)*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
18.6% (n=43) @ 24wk*b,c,e,d
NCT00365599 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
29.9% (n=45)c,e,d
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
3 other source trials
19.3% (n=119)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
17.5% (n=114)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
25.2% (n=115)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30% (n=47)c,e,d
NCT02668666 · Phase 2 · registry result, not featured evidence
Overall Survival
time to event · months
20.2 vs 22.5 Exemestane monthsa,c,d
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
20.1 vs 22.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
47.2 vs 43.9 Endocrine Therapy monthsc,d
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
4 other source trials
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
16.6 vs 13.8 Anastrozole months500 mgc,d
NCT01602380 · Phase 3 · combination
9 other source trials
4.1 vs 3.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
4.8 vs 3.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
7.5 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
8 vs 10.6 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
4.7 vs 3.8 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
4.1 vs 3.8 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
5.9 vs 3.3 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
20.2 vs 15.6 Endocrine Therapy monthsc,d
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
8 months500 mgb,c,e,d
NCT01300351 · Phase 3 · registry result, not featured evidence
9 other source trials
29.4 months*
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted
5.4 months
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
8 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
5.6 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
5.6 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
1.8 months
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
1.8 months
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
4.62 months*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to months from 20 weeks as posted
5.54 months*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to months from 24 weeks as posted
9.13 monthsb,c,e,d
NCT02668666 · Phase 2 · registry result, not featured evidence
1 other source trial
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
Time to Progression
time to event · months
No placebo or comparator arm
13.5 monthsa,b,c,d
NCT00075764 · Phase 3 · registry result, not featured evidence
show 1 more dose
15 months
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
10.3 monthsb,c,d
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
89.1%500 mgf
NCT01602380 · Phase 3 · combination
show 39 more results
47.5%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.2%
NCT02447328 · Phase 4 · registry result, not featured evidence
0%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
0%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
n/a: no completion milestoneArm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
21.6%
NCT00390455 · Phase 3 · registry result, not featured evidence
32.4%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
64.7%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
8.2%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
99.2%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
100%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
92.1%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
0%Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
9.1%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
12.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
3.4%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
29.6%E+OFSf
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
26.7%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
10%TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
9.1%TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
3.2%Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
20%Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
0%
NCT01614210 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
17.6%
NCT00499083 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—500 mgf
NCT01602380 · Phase 3 · combination
show 39 more results
10%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—
NCT02447328 · Phase 4 · registry result, not featured evidence
—Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
—Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
2%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
1.4%Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
3.4%Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
11.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
0%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
5%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
15.7%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
11.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.3%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
—Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
—
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
13.2%E+OFSf
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
6.8%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
—
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
—TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
—TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
—Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
—
NCT01614210 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT00499083 · Phase 2 · registry result, not featured evidence
Serious AEs
17.1%500 mgf
NCT01602380 · Phase 3 · combination
show 39 more results
25%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
16.9%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
13.8%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
14.1%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
6.2%Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
13.8%Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
—Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
8.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
3.7%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
15.6%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
25%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30.2%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
66.7%Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
18.5%Crizotinib Oral Capsule [Xalkori]
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
0%Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
18.2%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
37.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
10.5%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
18.5%Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
6.3%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
37.5%E+OFSf
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
37.2%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
28.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
20.7%TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
22.9%TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
0%Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
0%Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
1.9%
NCT01614210 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
33.3%
NCT00499083 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
500 mgf
arthralgia 18.4%
fatigue 12.7%
hot flush 11.4%
NCT01602380 · Phase 3 · combination
show 32 more results
hyperglycaemia 90%
stomatitis 37.5%
diarrhoea 35%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
myalgia 12.3%
nausea 12.3%
back pain 11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
lethargy 64.5%
arthralgia 42%
hot flush 37.2%
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
lethargy 64.4%
vomiting 44.9%
arthralgia 43.6%
NCT00253422 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
fatigue (asthenia, lethargy, malaise) 60.2%
hot flashes/flushes 45.7%
pain - joint 45.1%
NCT00075764 · Phase 3 · registry result, not featured evidence
fatigue (asthenia, lethargy, malaise) 63.2%
hot flashes/flushes 54.3%
pain - joint 44%
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
diarrhea 62.4% (placebo 21.9%)
fatigue 55.3% (placebo 53.3%)
rash acneiform 41.1% (placebo 4.4%)
NCT00390455 · Phase 3 · registry result, not featured evidence
500 mg
injection site reaction 11%
pyrexia 10.1%
fatigue 8.3%
NCT01300351 · Phase 3 · registry result, not featured evidence
arthralgia 11.7%
fatigue 10.5%
nausea 9%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
fatigue 83.3%
anemia 62.5%
neutrophil count decreased 60.4%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 64.6%
hyperglycaemia 59.8%
nausea 46.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
asthenia 100%
blood creatinine increased 100%
diarrhoea 100%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 68.3%
hyperglycaemia 64.3%
nausea 54%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 67.5%
diarrhoea 54%
nausea 40.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70%
hyperglycaemia 60%
fatigue 50%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
alanine aminotransferase increased 66.7%
aspartate aminotransferase increased 66.7%
dyspnea 50%
NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy
aspartate aminotransferase increased 74.1%
nausea 74.1%
alanine aminotransferase increased 63%
NCT03620643 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
vomiting 60%
anorexia 40%
constipation 40%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 81.8%
anorexia 63.6%
aspartate aminotransferase increased 45.5%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 91.7%
fatigue 50%
nausea 50%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 61.4%
thrombocytopenia 61.4%
nausea 59.6%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 55.6%
thrombocytopenia 55.6%
diarrhea 51.9%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
fatigue 53.1%
nausea 50%
achiness 43.8%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
fatigue 76.9%
anorexia 61.5%
pain 53.8%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
f
hot flashes/flushes 81.9%
pain - joint 77.7%
fatigue (asthenia, lethargy, malaise) 59%
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
hot flashes/flushes 80%
pain - joint 69.5%
sweating (diaphoresis) 61.7%
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
other/minor (not categorized) 24%
bone pain 20.9%
fatigue 15.6%
NCT00295646 · Phase 3 · registry result, not featured evidence
bone pain 29.3%
other/minor (not categorized) 24.9%
fatigue 18.2%
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
hot flashes 36.5%
nausea 21.2%
fatigue 9.6%
NCT01614210 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
bone pain 33.3%
hypokalemia 33.3%
mucositis oral 33.3%
NCT00499083 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dThe assessment timepoint is not available for both results.
  5. eTreatment context has not been resolved for both arms.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fulvestrant

All-cause Mortality 68.3% (n=230) vs 67.7% (n=232) Anastrozole500 mg
absolute value · percentage points
NCT01602380 · Phase 3 · combination
ORR 46.1% (n=193) vs 44.9% (n=196) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 5 more results
32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
20% (n=101) vs 9% (n=103) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
13% (n=32) vs 23% (n=32) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
38% (n=8) vs 17% (n=13) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
Duration of Response 20 vs 13.2 Anastrozole months500 mg
time to event · months
NCT01602380 · Phase 3 · combination
show 6 more results
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
10.2 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
8.7 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
22.3 vs 18.2 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Clinical Benefit 78.3% (n=230) vs 74.1% (n=232) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 3 more results
58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
55% (n=258) vs 55.1% (n=256) Anastrozole
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
ORR 7.1% (n=226) vs 4.2% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 16 Participants as posted
show 2 more results
7.3% (n=233) vs 4.2% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
22.8% (n=206) vs 29.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
Clinical Benefit 24.3% (n=226) vs 23.8% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
show 2 more results
28.3% (n=233) vs 23.8% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 Participants as posted
76.2% (n=206) vs 82.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
Duration of Clinical Benefit 11.2 vs 12.2 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
11.5 vs 12.2 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
18.5 vs 18.1 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Time to Treatment Failure 3.8 vs 3.4 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
3.9 vs 3.4 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
12.4 vs 11.4 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -1.09 vs -4.97 Capecitabine score
absolute change · score
Role functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 6.78 vs 8.67 Capecitabine score
absolute change · score
Emotional functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 61 further endpoints in the CSV export.

Tamoxifen (Soltamox)

Disease-free Survival 86.6% (n=1015) vs 84.7% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
89% (n=1014) vs 84.7% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Breast Cancer-free Interval 88.4% (n=1015) vs 86.4% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
90.9% (n=1014) vs 86.4% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Distant Recurrence-free Interval 91.3% (n=1015) vs 90.7% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
93% (n=1014) vs 90.7% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 93.3% (n=1015) vs 91.5% (n=1018) Tamoxifen @ 416wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
92.1% (n=1014) vs 91.5% (n=1018) Tamoxifen @ 416wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Disease-free Survival NA vs NA Anastrozole months
time to event · months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
Recurrence-free Survival NA vs NA Anastrozole months
time to event · months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
OS Rate at 12 75.63% (n=49) @ 104wk
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Overall 74.2% (n=31)
responder rate · % of participants
No placebo or comparator arm
NCT01831076 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
show 2 more results
0% (n=5)*
NCT01831076 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
100% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 13 participants as posted
Pathologic Complete 0% (n=23) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT02988986 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 2 more results
7.7% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted
14.3% (n=14)*
NCT00499083 · Phase 2 · registry result, not featured evidence · converted to % from 2 participants as posted
Ki67 -40% (n=44) @ 1wk
absolute change · percentage points
No placebo or comparator arm
NCT01614210 · Phase 2 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulvestrant's landscape · Tamoxifen (Soltamox)'s landscape